In 1994, Lapidot et al. demonstrated that rare AML cells with a CD34+CD38− phenotype could initiate leukemia in immunodeficient mice (Lapidot et al., 1994), establishing this population as enriched for LSC activity. The gene discussed is CD34; the disease is acute myeloid leukemia.